NCT06876142 2026-04-16
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Suspended
Clinical Trials
8 trialsNCT06159166 2026-04-13
Mirda
Johns Hopkins University
Phase 1/2 Recruiting
NCT06843967 2026-03-13
A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Recruiting
NCT04923126 2026-02-04
SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma
St. Jude Children's Research Hospital
Phase 1/2 Recruiting
NCT02039336 2025-07-08
M13DAP
The Netherlands Cancer Institute
Phase 1/2 Completed
NCT05054374 2025-05-23
A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT05580770 2025-02-17
Mirdametinib + BGB-3245 in Advanced Solid Tumors
SpringWorks Therapeutics, Inc.
Phase 1/2 Terminated
NCT00147550 2013-09-13
MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.
Pfizer
Phase 1/2 Terminated